Shubham Pant, MD, MBBS

Shubham Pant, MD, MBBS, is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Articles

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

May 15th 2025

Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.

Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

April 2nd 2025

Panelists discuss how recent research presentations and data updates at the latest scientific meeting have advanced the understanding and treatment landscape of biliary tract cancer (BTC).

Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

March 26th 2025

Panelists discuss how significant challenges remain in HER2-positive biliary tract cancer (BTC), including optimizing sequencing of targeted therapies, addressing resistance mechanisms, improving biomarker testing accessibility, and developing strategies for brain metastases.

Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

March 26th 2025

Panelists discuss how treatment selection among HER2-targeted agents for biliary tract cancer (BTC) depends on multiple factors including patient characteristics and prior therapies, while also considering the role of traditional chemotherapy regimens such as FOLFOX in specific clinical scenarios.

Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

March 19th 2025

Panelists discuss how the MyPathway study and SGNTUC-019 basket trial demonstrated the clinical activity of trastuzumab plus pertuzumab and tucatinib, respectively, in HER2-positive biliary tract cancer (BTC), highlighting key efficacy metrics and safety profiles that inform treatment selection.

New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

March 19th 2025

Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.

Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

March 12th 2025

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.

Understanding HER2 Testing in BTC: Detection and Clinical Approaches

March 12th 2025

Panelists discuss how molecular testing strategies at disease progression are evolving in biliary tract cancer (BTC), with particular focus on HER2-amplification detection methods including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS), while noting that HER2 positivity occurs in approximately 5% to 15% of cases.

Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

March 5th 2025

Panelists discuss how emerging clinical trial data for immunotherapy combinations in first-line advanced biliary tract cancer (BTC) can be effectively translated into real-world treatment decisions, weighing factors such as biomarker status, safety profiles, and treatment sequencing.

Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

March 5th 2025

Panelists discuss how the practice-changing TOPAZ-1 trial established durvalumab plus gemcitabine/cisplatin as a first-line standard for advanced biliary tract cancer (BTC) while exploring key clinical factors that influence the choice between durvalumab and pembrolizumab-based combinations following the KEYNOTE-966 results.

Expert Insights: Challenges With ctDNA Testing in BTC

February 26th 2025

Panelists discuss how circulating tumor DNA (ctDNA) testing in biliary tract cancer (BTC) presents unique technical and interpretative challenges, including considerations around sensitivity, timing of collection, and clinical validation of results.

Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

February 26th 2025

Panelists discuss how clinicians are increasingly utilizing both tissue and liquid biopsies with comprehensive DNA/RNA next-generation sequencing (NGS) for biomarker testing in biliary tract cancer (BTC), while noting variations in testing practices across different treatment centers.

The Importance of Early Biomarker Testing in Managing Advanced BTC

February 19th 2025

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.

Guiding Patients Through Advanced BTC Prognosis and Expectations

February 19th 2025

Panelists discuss how physicians typically communicate survival outcomes and prognosis to patients with newly diagnosed advanced biliary tract cancer (BTC), focusing on setting realistic expectations while maintaining hope.

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

November 22nd 2024

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Dr Pant on the Utility of Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer

June 20th 2024

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Dr Pant on the Background of the RAGNAR Trial in FGFR-altered Solid Tumors

June 28th 2023

Shubham Pant, MD, MBBS, discusses the background of the ongoing phase 2 RAGNAR trial evaluating the use of erdafitinib in patients with solid tumors harboring FGFR alterations.

Dr Pant on the Investigation of Adagrasib in KRAS G12C–Mutated Solid Tumors

June 21st 2023

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

Dr Pant on the Investigation of Zanidatamab in Biliary Tract Cancer

June 9th 2023

Shubham Pant, MD, MBBS, discusses the rationale for the phase 2b HERIZON-BTC-01 trial and shares the results with zanidatamab in previously treated HER2-amplified biliary tract cancer.